ORIC
ORIC Pharmaceuticals, Inc.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable
2-Year Price History
Quarterly Financials & Projections
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Est | 2027-Q4 | 0.0 | 0.0 | -- | 0.0 | -- | 0.0 | -0.0 | 281.9 | -- | -- | -- | -- | -- |
| Est | 2027-Q3 | 0.0 | 0.0 | -- | 0.0 | -- | 0.0 | -0.0 | 281.9 | -- | -- | -- | -- | -- |
| Est | 2027-Q2 | 0.0 | 0.0 | -- | 0.0 | -- | 0.0 | -0.0 | 281.9 | -- | -- | -- | -- | -- |
| Est | 2027-Q1 | 0.0 | 0.0 | -- | 0.0 | -- | 0.0 | -0.0 | 281.9 | -- | -- | -- | -- | -- |
| Est | 2026-Q4 | 0.0 | 0.0 | -- | 0.0 | -- | 0.0 | -0.0 | 281.9 | -- | -- | -- | -- | -- |
| Est | 2026-Q3 | 0.0 | 0.0 | -- | 0.0 | -- | 0.0 | -0.0 | 281.9 | -- | -- | -- | -- | -- |
| Est | 2026-Q2 | 0.0 | 0.0 | -- | 0.0 | -- | 0.0 | -0.0 | 281.9 | -- | -- | -- | -- | -- |
| Est | 2026-Q1 | 0.0 | 0.0 | -- | 0.0 | -- | 0.0 | -0.0 | 281.9 | -- | -- | -- | -- | -- |
| Act | 2026-Q1 | 0.0 | -39.4 | -39.6 | -35.8 | -32.4 | -32.4 | -0.0 | 281.9 | 0.0 | 105.5 | -71.4% | -- | -- |
| Act | 2025-Q4 | 0.0 | -30.2 | -34.6 | -30.5 | -22.5 | -22.9 | -0.4 | 281.5 | 11.6 | 87.8 | -67.3% | -- | -- |
| Act | 2025-Q3 | 0.0 | -32.3 | -36.7 | -32.6 | -25.1 | -25.2 | -0.0 | 287.1 | 3.3 | 99.0 | -65.8% | -- | -- |
| Act | 2025-Q2 | 0.0 | -38.8 | -39.1 | -36.4 | -30.8 | -30.9 | -0.1 | 282.5 | 3.3 | 78.1 | -110.0% | -- | -- |
| Act | 2025-Q1 | 0.0 | -32.4 | -32.7 | -30.0 | -32.8 | -33.2 | -0.4 | 203.7 | 3.2 | 71.0 | -341.9% | -- | -- |
| Act | 2024-Q4 | 0.0 | -36.0 | -39.6 | -36.3 | -28.1 | -28.3 | -0.2 | 256.0 | 3.2 | 70.7 | -253.1% | -- | -- |
| Act | 2024-Q3 | 0.0 | -38.1 | -38.3 | -34.6 | -28.8 | -29.2 | -0.4 | 272.4 | 3.1 | 70.5 | -161.7% | -- | -- |
| Act | 2024-Q2 | 0.0 | -35.7 | -36.0 | -32.0 | -25.6 | -26.0 | -0.3 | 286.4 | 2.8 | 70.4 | -115.5% | -- | -- |
| Act | 2024-Q1 | 0.0 | -28.7 | -29.0 | -25.0 | -30.4 | -30.6 | -0.2 | 316.8 | 2.8 | 67.4 | -75.7% | -- | -- |
| Act | 2023-Q4 | 0.0 | -28.1 | -31.4 | -28.3 | -24.3 | -24.3 | -0.1 | 208.2 | 10.2 | 57.5 | -221.1% | -14.1x | -- |
| Act | 2023-Q3 | 0.0 | -28.4 | -28.7 | -25.5 | -19.6 | -19.7 | -0.1 | 227.3 | 2.7 | 57.4 | -155.5% | -- | -- |
| Act | 2023-Q2 | 0.0 | -24.7 | -25.0 | -22.9 | -21.1 | -21.6 | -0.4 | 264.2 | 2.7 | 45.7 | -103.5% | -- | -- |
| Act | 2023-Q1 | 0.0 | -25.4 | -25.7 | -24.0 | -20.6 | -20.9 | -0.3 | 189.6 | 2.7 | 45.1 | -331.3% | -- | -- |
| Act | 2022-Q4 | 0.0 | -21.9 | -22.1 | -20.9 | -15.3 | -15.6 | -0.3 | 206.3 | 12.1 | 40.1 | -145.7% | -- | -- |
| Act | 2022-Q3 | 0.0 | -20.5 | -25.7 | -24.8 | -19.3 | -19.7 | -0.4 | 193.7 | 2.6 | 39.6 | -231.7% | -- | -- |
| Act | 2022-Q2 | 0.0 | -20.5 | -20.7 | -20.3 | -17.8 | -18.4 | -0.7 | 227.1 | 2.6 | 39.5 | -122.9% | -- | -- |
| Act | 2022-Q1 | 0.0 | -23.0 | -23.3 | -23.2 | -22.7 | -23.4 | -0.7 | 234.6 | 2.0 | 39.4 | -110.4% | -- | -- |
AI Analysis
LLM Evaluations
ORIC is a high-risk, high-reward clinical-stage biotech trading near analyst consensus discount with two potentially differentiated assets: rinzimetostat (PRC2 inhibitor for mCRPC) showing encouraging 55% PSA50 response rates, and enozertinib showing best-in-class CNS penetration in NSCLC. The ~$280M cash position provides runway into 2H 2028, sufficient to reach key Phase 3 data readouts. However, the Ipsen/Tazverik withdrawal creates genuine class-wide overhang on the EZH2/PRC2 mechanism, 45.8% short interest reflects deep skepticism, and the 24%+ annual dilution rate structurally destroys per-share value. With zero revenue, the entire $1.26B market cap is option value on clinical success. The risk/reward is balanced at current levels - the clinical data is genuinely encouraging, but the regulatory/safety overhang and binary nature of the outcomes make this a neutral-to-speculative position rather than a high-conviction call.
Valuation & Metrics
Market Stats
TTM Financial Snapshot
DCF Fair Value Estimate
Forward Outlook & Risk
Short Interest
Options
| Strike | Call Bid/Ask | Call OI | Put Bid/Ask | Put OI |
|---|---|---|---|---|
| $5.00 | $1.50/$6.00 | 0 | --/$4.90 | 0 |
| $6.00 | $1.30/$5.50 | 0 | --/$0.65 | 51 |
| $7.00 | $0.10/$4.90 | 0 | --/$4.90 | 0 |
| $8.00 | $0.10/$4.90 | 0 | --/$3.60 | 3 |
| $9.00 | --/$4.90 | 0 | $0.10/$4.90 | 2 |
| $10.00 | --/$4.90 | 5 | $0.20/$4.90 | 4 |
| $11.00 | --/$4.90 | 1 | $1.00/$5.50 | 0 |
| $12.00 | --/$4.90 | 1 | $1.70/$6.50 | 7 |
Forward Projections & Estimates
Employees
Cash Runway
Institutional Ownership
Headline & net flow
In Q1 2026 so far (quarter still filing), institutions are net buyers — bought 24.6% of float, sold 20.4%. 4 filers moved >1% of shares (3 buying, 1 selling).
Ownership composition
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| Nextech Invest, Ltd. | $90.8M | $6.78 | +$0 | +$23.8M | +28.2% | $1.42B |
| EcoR1 Capital, LLC | $85.2M | $12.00 | +$0 | +$41.9M | -4.9% | $2.34B |
| BlackRock, Inc.Passive | $75.8M | $10.19 | +$1.4M | +$7.0M | -0.2% | $5.69T |
| VIKING GLOBAL INVESTORS LP | $73.8M | $10.72 | −$9.5M | −$9.5M | +1.1% | $35.75B |
| PRICE T ROWE ASSOCIATES INC /MD/ | $68.3M | $11.30 | +$26.5M | +$51.4M | -0.2% | $864.93B |
| SR ONE CAPITAL MANAGEMENT, LP | $58.5M | $10.15 | +$0 | +$58.5M | -7.7% | $915M |
| PFIZER INC | $57.7M | $8.07 | −$7.6M | −$7.2M | +3.0% | $239M |
| ALKEON CAPITAL MANAGEMENT LLC | $57.1M | $7.34 | +$0 | +$6.3M | +1.1% | $22.08B |
| VR Adviser, LLC | $54.7M | $10.37 | −$17.2M | +$14.4M | -2.2% | $2.68B |
| NEA Management Company, LLC | $52.2M | $10.73 | +$0 | +$24.4M | -3.4% | $1.76B |
| STATE STREET CORPPassive | $46.9M | $9.42 | −$7.0M | +$19.1M | -0.2% | $2.89T |
| Column Group LLC | $44.9M | $5.34 | +$0 | +$0 | -8.5% | $101M |
| Siren, L.L.C. | $38.0M | $11.86 | +$25.2M | +$25.2M | +6.2% | $3.61B |
| ORBIMED ADVISORS LLC | $34.1M | $11.10 | −$12.0M | +$25.3M | -8.1% | $4.38B |
| AIHC Capital Management Ltd | $31.2M | $12.67 | +$31.2M | +$31.2M | +23.4% | $120M |
| FMR LLC | $30.8M | $9.23 | −$568K | −$587K | +0.3% | $1.89T |
| CITADEL ADVISORS LLC | $30.7M | $8.02 | −$152K | +$24.2M | -0.4% | $138.22B |
| First Turn Management, LLC | $25.6M | $10.29 | +$88K | −$129K | +0.2% | $854M |
| Vivo Capital, LLC | $23.4M | $7.52 | −$3.4M | −$2.9M | -6.9% | $1.20B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $23.3M | $9.27 | +$1.1M | +$6.8M | +2.3% | $1.61T |
Trading behavior
▸ Compare to holder-profile behavior (across all their stocks)
Biggest decreases this quarter
New buyers this quarter
Top-5 holders · 27.2%
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
| Ticker | Name | Co-holders | Score |
|---|---|---|---|
| ZBIO | Zenas BioPharma, Inc. | 5 | 222.10× |
| CRSP | CRISPR Therapeutics AG | 4 | 195.45× |
| GLUE | Monte Rosa Therapeutics, Inc. | 3 | 162.87× |
| ERAS | Erasca, Inc. | 4 | 108.58× |
| CELC | Celcuity Inc. | 4 | 97.72× |
| DNTH | Dianthus Therapeutics, Inc. | 4 | 75.17× |
| COGT | Cogent Biosciences, Inc. | 5 | 74.03× |
| ACLX | Arcellx, Inc. | 3 | 52.35× |
| ABVX | Abivax S.A. | 3 | 35.75× |
| RVMD | Revolution Medicines, Inc. | 3 | 27.14× |
Analyst Coverage
Corporate
Executive Compensation (2023-2025)
Insider Trading (last 12mo)
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-02-24 | SELL | Piscitelli Dominic | officer: Chief Financial Officer | 52,000 | $13.51 | $703K | $921K |
| 2026-01-16 | SELL | Heyman Richard A. | director | 6,700 | $12.00 | $80K | $502K |
| 2025-12-16 | SELL | Chacko Jacob | director, officer: PRESIDENT AND CEO | 33,374 | $9.06 | $302K | $5.27M |
| 2025-12-16 | SELL | Multani Pratik S | officer: Chief Medical Officer | 10,720 | $9.06 | $97K | $617K |
| 2025-12-16 | SELL | Piscitelli Dominic | officer: Chief Financial Officer | 10,720 | $9.06 | $97K | $617K |
| 2025-10-06 | SELL | Chacko Jacob | director, officer: PRESIDENT AND CEO | 37,461 | $12.32 | $462K | $6.55M |
| 2025-10-06 | SELL | Piscitelli Dominic | officer: Chief Financial Officer | 11,000 | $14.52 | $160K | $702K |
| 2025-10-01 | SELL | Chacko Jacob | director, officer: PRESIDENT AND CEO | 53,001 | $12.05 | $639K | $6.86M |
| 2025-09-30 | SELL | Chacko Jacob | director, officer: PRESIDENT AND CEO | 34,538 | $12.01 | $415K | $7.47M |
| 2025-09-22 | SELL | Chacko Jacob | director, officer: PRESIDENT AND CEO | 125,000 | $10.80 | $1.35M | $7.09M |
| 2025-07-01 | SELL | Piscitelli Dominic | officer: Chief Financial Officer | 20,000 | $10.05 | $201K | $486K |
| 2025-06-24 | SELL | Piscitelli Dominic | officer: Chief Financial Officer | 32,466 | $10.50 | $341K | $718K |
| 2025-06-23 | SELL | Piscitelli Dominic | officer: Chief Financial Officer | 1,034 | $10.00 | $10K | $1.01M |
| 2025-06-23 | BUY | You Angie | director | 1,403 | $9.43 | $13K | $264K |
| 2025-06-20 | BUY | You Angie | director | 26,597 | $9.39 | $250K | $250K |
| 2025-06-12 | SELL | Piscitelli Dominic | officer: Chief Financial Officer | 300 | $10.00 | $3K | $1.02M |
| 2025-06-11 | SELL | Piscitelli Dominic | officer: Chief Financial Officer | 2,976 | $10.01 | $30K | $1.02M |
| 2025-06-10 | SELL | Piscitelli Dominic | officer: Chief Financial Officer | 324 | $10.00 | $3K | $1.05M |
| 2025-06-09 | SELL | Piscitelli Dominic | officer: Chief Financial Officer | 300 | $10.00 | $3K | $1.04M |
| 2025-06-06 | SELL | Piscitelli Dominic | officer: Chief Financial Officer | 2,600 | $10.01 | $26K | $1.04M |
Order Flow (FINRA, ~3w lag)
Filing Risk Analysis
Filing Risk Scores
ORIC: Dilution Engine Funding Clinical Burn
Counter-Thesis
Counter-Thesis & Recent News
In February and March 2026, ORIC reported robust Phase 1b data for its two lead assets: rinzimetostat (ORIC-944) for prostate cancer and enozertinib (ORIC-114) for lung cancer. Rinzimetostat achieved a 55% PSA50 response and a notable 59% ctDNA clearance rate. Enozertinib demonstrated 'best-in-class' potential with a 100% intracranial objective response rate (ORR) in patients with brain metastases. Furthermore, ORIC confirmed a cash position of approximately $413 million, extending its runway into 2H 2028, and announced the planned initiation of its first Phase 3 trial for rinzimetostat in 1H 2026 (Source: GlobeNewswire, Seeking Alpha).
The prevailing bear thesis is driven by the recent withdrawal of Ipsen's Tazverik from the market due to secondary malignancies, which has triggered a sector-wide sell-off of EZH2/PRC2 inhibitors. Bears argue that ORIC faces severe regulatory headwinds and the possibility of similar class-wide safety issues. Additionally, as a clinical-stage company with no revenue, ORIC remains a 'binary' bet where any Phase 3 setback could result in a total loss of value, compounded by high R&D spend and a pivot away from early-stage discovery (Source: Investing.com, Finviz).
The most significant red flag is the regulatory scrutiny on the EZH2 inhibitor class following the Ipsen setback. There is also concern regarding the company's decision to 'substantially reduce' investment in its discovery research to preserve cash for late-stage trials, which may limit the long-term pipeline. Furthermore, while the current cash runway is long, any delays in Phase 3 enrollment could lead to further dilutive capital raises before commercialization (Source: Public.com, OricPharma.com).
ORIC faces intense competition from large-cap players, specifically Pfizer, whose MEVPRO-1 Phase 3 study in the PRC2/EZH1 pathway is a direct competitor to rinzimetostat. In the NSCLC space, enozertinib must compete against established and emerging EGFR/HER2 inhibitors, although ORIC is attempting to differentiate via superior CNS penetration and a strategic collaboration with Johnson & Johnson (Source: MarketBeat).
Sentiment among institutional analysts remains surprisingly resilient. JPMorgan reiterated an 'Overweight' rating and a $21 target in March 2026, citing 'safety differentiation' supported by Key Opinion Leader (KOL) feedback. Technical indicators also suggest a contrarian opportunity: the stock's Relative Strength Index (RSI) recently hit 26.30, signaling 'oversold' territory, while the consensus analyst price target of ~$21.23 represents a potential 50%+ upside from current depressed levels (Source: DirectorsTalk Interviews, Investing.com).